Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective

Athena Kritharis,1 Hanny Al-Samkari2 and David J Kuter2
1Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ and 2Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

ABSTRACT

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a common autosomal dominant disorder that causes abnormal blood vessel formation. The diagnosis of hereditary hemorrhagic telangiectasia is clinical, based on the Curaçao criteria. Genetic mutations that have been identified include ENG, ACVR1/ALK1, and MADH4/SMAD4, among others. Patients with HHT may have telangiectasias and arteriovenous malformations in various organs and suffer from many complications including bleeding, anemia, iron deficiency, and high-output heart failure. Families with the same mutation exhibit considerable phenotypic variation. Optimal treatment is best delivered via a multidisciplinary approach with appropriate diagnosis, screening and local and/or systemic management of lesions. Antiangiogenic agents such as bevacizumab have emerged as a promising systemic therapy in reducing bleeding complications but are not curative. Other pharmacological agents include iron supplementation, antifibrinolytics and hormonal treatment. This review discusses the biology of HHT, management issues that face the practising hematologist, and considerations of future directions in HHT treatment.

Introduction

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a common autosomal dominant disorder that causes abnormal blood vessel formation.1 The eponym recognizes the 19th century physicians William Osler, Henri Jules Louis Marie Rendu, and Frederick Parkes Weber, who each independently described the disease.2 Clinical sequelae of HHT include mucocutaneous telangiectasias, arteriovenous malformations (AVMs), and bleeding, with consequent iron deficiency anemia. Patients with HHT have been found to have abnormal plasma concentrations of transforming growth factor-beta (TGF-β)3 and vascular endothelial growth factor (VEGF)4 secondary to mutations in ENG, ACVR1 and MADH4.5 There is considerable inter- and intra-family variation in disease onset and clinical severity, even in cases resulting from an identical mutation. Iron deficiency and associated anemia are frequent complications of the disease due to recurrent epistaxis and/or gastrointestinal bleeding. There are no accepted guidelines on management of patients with HHT beyond supportive measures of iron supplementation, red cell transfusion, and directed treatments to ablate bleeding sites and AVMs.

Bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis via VEGF inhibition, appears to be promising in HHT as an intravenous formulation for reducing the frequency and severity of epistaxis and impacting quality of life.6,7 However, data on intranasal bevacizumab have been conflicting, and studies investigating the use of intranasal bevacizumab are limited to case reports and retrospective series.6 Treatment of HHT involves a multidisciplinary approach of specialists in cardiology, pulmonology, hepatology, interventional radiology, ear, nose and throat (ENT), genetics, and hematology. This
review focuses on the biology of HHT and the management issues that confront the hematologist, as well as proposing a hematology management scheme.

**Pathogenesis**

**Pathology**

Hereditary hemorrhagic telangiectasia is a disease characterized by vascular lesions, including AVMs and telangiectasias. AVMs are abnormal connections that form between arteries and veins without an intermediary capillary system. They can occur anywhere in the body, such as in the central nervous system (CNS), lungs, liver or spine. Vascular malformations may be composed of small (nidi 1-3 cm) or micro (nidi <1 cm) AVMs, pulmonary sacs, or direct high-flow connections. While the terms “telangiectasia” and “arteriovenous malformation” are often used interchangeably, they both occur from a direct connection between an artery and a vein whilst bypassing the capillary system, they are actually pathologically-distinct terms. Telangiectasias, by definition, occur on mucocutaneous surfaces, such as the skin, gastrointestinal (GI) mucosa, or upper aerodigestive tract. AVMs occur in internal organs, such as the liver, lung, and brain. Histological evaluation of AVMs reveals an irregular endothelium, increased collagen and actin, and a convoluted basement membrane.

**Gene mutations**

Gene mutations that have been described in HHT include *ENG*, *ACVRL1* (also known as *ALK1*), and *MADH4* (also known as *SMAD4*), as well as other postulated loci (Table 1).^11,12^

- In 1994, *ENG*, located on chromosome 9q34 and encoding for the protein endoglin (CD105), was the first gene identified in which mutations resulted in HHT, and so HHT due to *ENG* mutations is known as HHT type 1 (HHT1).^13^ Endoglin is a cell-surface glycoprotein that functions as part of the transforming growth factor beta (TGF-β) signaling complex that plays an important role in angiogenesis and vascular remodeling.

- In 1996, defects in the *ACVRL1* gene on chromosome 12q13, which encodes for the activin receptor-like kinase 1 (ALK1), were recognized to cause HHT, and defects in this gene result in HHT type 2 (HHT2). Like endoglin, ALK1 is a cell-surface protein that is part of the TGF-β signaling pathway and is important in the regulation of angiogenesis. ^14,15^

- Mutations in *MADH4* (which encodes for the SMAD4 protein, a transcription factor that mediates signal transduction in the TGF-β pathway^16^) result in a juvenile polyposis with HHT syndrome (JP-HHT), described later in this review.

Over 80% of HHT patients have identifiable mutations,^16,17^ leaving approximately 20% who meet clinical diagnostic criteria but do not have definitive mutations. Of those with a pathogenic mutation, 61% have *ENG* mutations, 57% have *ACVRL1* mutations, and 2% have *MADH4* mutations;^18^ very small minorities of patients have pathogenic mutations in other genes, described below. Over 600 different mutations have been uncovered in *ENG* and *ACVRL1* in all exons as well as exon/intron boundaries and splice-sites. Frameshift and nonsense mutations appear to be more frequent in *ENG*.

Additional loci associated with HHT have been identified on chromosomes 5q31 (HHT3) and 7q14 (HHT4), but have not been completely characterized.^4,19,20^ Bone morphogenetic protein 9 (BMP9, also known as growth differentiation factor 2 or GDF2), encoded by *BMP9* (also called *GDF2*), is a ligand for the *ACVRL1* gene product ALK1. Consequently, mutations in *BMP9/GDF2* result in the clinical manifestations of HHT and are referred to as HHT-5. In addition, pathogenic mutations in the *RASA1* gene have also been associated with a clinical syndrome consistent with HHT as well as other vascular anomalies. Little is known about *RASA1*-mutated HHT.

**Pathophysiology**

All three identified causative genes are involved in cell signaling via the TGF-β/BMP signaling pathway, which has roles in cell growth, apoptosis, smooth muscle cell differentiation, and vascular remodeling and maintenance. ^21^ The vasculature normally develops from the capillary system with the activation and growth of endothelial cells, the intercellular junctions between them, and the maturation of the basement membrane. ^22^ Capillaries then develop into larger vessels with the recruitment of smooth muscle cells to the endothelial wall where TGF-β is essential.

In the healthy patient, ligands in the extracellular space such as TGF-β, activins and BMPs bind to type I and type II serine/threonine receptors of the cell membrane. TGF-β1/2/3 ligand binds to the type II receptor of the TGF-β signaling cascade (TGFBRII) that becomes phosphorylated and recruits the TGF-β type I receptors ALK1 or ALK5. Endoglin is an endothelial specific receptor that associates

<table>
<thead>
<tr>
<th>Table 1. Classification and genetics of the most common hereditary human telangiectasia (HHT) subtypes.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
</tr>
<tr>
<td>HHT type 1</td>
</tr>
<tr>
<td>HHT type 2</td>
</tr>
<tr>
<td>Combined syndrome of HHT and JP-HHT</td>
</tr>
</tbody>
</table>

AVM: arteriovenous malformations; JP-HHT: juvenile polyposis HHT.
with multiple receptor complexes of the TGF-β receptor complex and also modulates ALK1 and ALK5. Circulating BMP9 has been demonstrated to bind strongly with endoglin and ALK1 receptors found abundantly in the surface membrane of endothelial cells. ALK1 receptors phosphorylate SMAD1/5/8 in the cytoplasm to form the SMAD1/5/8-SMAD4 complex that translocates to the nucleus to promote normal endothelial cell proliferation and smooth muscle migration. In contrast, the ALK5 pathway works through SMAD2/3 to inhibit normal endothelial cell proliferation and smooth muscle migration. The result is contrasting responses that balance endothelial proliferation, angiogenesis and smooth muscle migration.

In patients with HHT, mutations in endoglin, ALK1, or one of several other proteins in this pathway alter the normal endothelial response. In HHT1, the ENG mutation leads to reduced endoglin, ALK1 and ALK5 signaling; in HHT2, the ALK1 mutation causes reduced ALK1 signaling alone. Mice with one functioning copy of Eng or Acvrl1 show clinical signs of HHT. The haploinsufficiency of these proteins along with a second hit, such as tissue injury, infection or hypoxia, likely cause the focal vascular lesions of HHT1 and HHT2 as reduced levels of endoglin or ALK1 cannot maintain the balance needed for normal blood vessel formation (recruitment of smooth muscle cells and proliferation of endothelial cells). Decreased TGF-β transcription normally mediated through this pathway, therefore, disrupts the vascular integrity and smooth muscle differentiation of the endothelium resulting in an abnormal cytoskeleton and fragile small vessels.

Vascular endothelial growth factor, an endothelial-specific factor for angiogenesis, is of major interest in diseases of vascular malformation and is elevated in HHT patients. VEGF production is stimulated by ALK5 (and SMAD2 through activation of ALK5) and inhibited by ALK1 (and SMAD1 through activation of ALK1). Therefore, any mutation along the ALK1 pathway (BMP9, ACVRL1, ENG, MADH4) results in elevation of VEGF through reduced ALK1 pathway signaling. VEGF drives many of the pathogenic manifestations of HHT, as normalizing VEGF has been shown to prevent AVMs in Acvrl1-deficient mice. This may be secondary to reduced angiogenic stimuli and reduction of feeding arteries from blocking the VEGF that would normally develop and maintain arteriovenous shunts.

Other factors that may contribute to the severity of disease include repeated injury and chronic inflammation in keeping with the two-hit hypothesis and stimulation of the ALK1 signaling pathway. An abnormal endothelium

Figure 1. Molecular pathophysiology of hereditary hemorrhagic telangiectasia (HHT). Physiological signaling via ALK1 and ALK5 receptors (activated via binding BMP9 and TGFβ) results in activation of different SMAD pathways, which converge at SMAD4 resulting in transcription of genes involved in angiogenesis. In HHT, mutations perturb signaling through ALK1 via mutations in the ALK1 receptor itself, its ligand BMP9, or its modulator, the glycoprotein membrane receptor endoglin. The result is decreased signaling through ALK1 and increased signaling through ALK5, perturbing normal endothelial proliferation and smooth muscle cell migration. Reduced ALK1 signaling and increased ALK5 signaling also result in higher vascular endothelial growth factor (VEGF) levels, causing increased endothelial proliferation (which may be exacerbated by stress or hypoxia), resulting in arteriovenous malformations (AVMs), telangiectasias, and the manifestations of HHT.
may also lead to defective synthesis of von Willebrand Factor (VWF) and prolonged bleeding. There have been reports of families affected by both von Willebrand disease (VWD) and HHT. This poses the question of a potential relationship between the two diseases, which has been studied in published case reports. A potential type IIA VWD mutation (Ile665 to Thr) has been identified in affected families.36

While this is a simplified discussion of complex vascular biology, it illustrates why mutations in ENG, ACVRL1/ALK1, MADH4/SMAD4, and BMP9/GDF2 result in the HHT phenotype. A streamlined schematic summarizing the normal physiological signaling of the TGF-β pathway and the pathophysiology of HHT is shown in Figure 1.

**Epidemiology and disease course**

Hereditary hemorrhagic telangiectasia affects approximately 1 in 5000 individuals in North America,37 but the highest prevalence is seen in the Afro-Caribbean regions of the Dutch Antilles and France.38 There is also variability regarding HHT subtype, with type 1 HHT being found more in North America and Europe and type 2 being more common in the Mediterranean and South America. However, these statistics may underestimate the actual disease prevalence as the diagnosis is often missed and some patients may be asymptomatic. HHT exhibits incomplete penetrance and clinical manifestations can vary between patients, even within families with known mutations.

Patients may relate a history of epistaxis in childhood, often apparent during adolescence. Mild epistaxis or bleeding tendencies increase with age and telangiectasias may be seen after adolescence, often in adulthood.1 Clinical signs of bleeding become more apparent in adulthood, often after the age of 40 years. Symptoms from anemia may be an initial complaint at presentation from gastro-intestinal bleeding, seen in approximately one-third of patients. Patients with mutations of ACVRL1 may present later in life, while those with MADH4 mutations may present earlier in childhood with juvenile colonic polyps and early onset colorectal cancer (at a mean age of 28 years).39

As a population, patients with HHT probably have a reduced life expectancy, but this is highly dependent on the severity of disease. Patients without internal organ manifestations (such as hepatic, cerebral or pulmonary AVMs) are expected to have a normal or near-normal lifespan, but approximately 10% of patients may die or become debilitated from vascular complications.40 In a large case-control study, 675 HHT patients were compared with age- and sex-matched healthy controls using a population-based UK primary care database. Patients with HHT were more likely to suffer from cerebral abscess, migraine, ischemic/embolic stroke, heart failure, colon cancer, and the numerous bleeding complications characteristic of the disease. The hazard ratio for death for patients with HHT compared with controls was 2.03 (CI: 1.59-2.60; P <0.0001).41 Life expectancy was seven years shorter in HHT patients in one study, with two mortality peaks, one under 50 years and one between 60-79 years of age.42 Finally, a population study in Denmark demonstrated mortality rates double that of the general population in those under 60 years of age.43

**Clinical manifestations**

Patients with HHT vary in disease severity and bleeding complications. This variability is likely attributed to other genes, inflammation, and the environment that modify the primary genetic defect. Common AVM complications include epistaxis, GI bleeding, iron deficiency, iron deficiency anemia, ischemic and hemorrhagic stroke, brain abscess, high output heart failure, and liver failure.

It is suggested that certain mutated genes in HHT may be associated with specific clinical manifestations. ENG mutations may be associated with more pulmonary and brain AVMs; ACVRL1 with more liver AVMs, spinal AVMs, epistaxis and pulmonary hypertension; and MADH4 with juvenile colonic polyposis.44

**Pulmonary AVMs**

Pulmonary AVMs will develop in at least 50% of HHT patients and are more common in HHT1 than HHT2. Since approximately 70% of pulmonary AVMs are due to HHT, the diagnosis of HHT1 should be considered in all patients with pulmonary AVMs. Migraines are quite frequent in patients with pulmonary AVMs.45 Between 5 and 80% of patients may have pulmonary AVMs that may be asymptomatic or present as hemoptysis, dyspnea, hypoxemia or digital clubbing. Brain abscesses and stroke may occur following “dirty” procedures (e.g. dental cleaning) if bacteria can bypass the pulmonary filtration system via right to left shunting from AVMs.46 Polycythemia may occur if there is significant AV shunting. The locus designated as HHT3 appears to predispose to pulmonary AVM formation.

**Liver AVMs**

Liver AVMs may be seen in up to 70% of patients with HHT. HHT2 appears to be associated with more liver AVMs. Although often asymptomatic, the shunting of blood through these AVMs in the liver can precipitate high-output heart failure, liver failure, or portal hypertension.

**High-output heart failure**

High-output heart failure can manifest due to large pulmonary AVMs and/or hepatic AVMs.47 High-output failure can be defined by: 1) symptoms of heart failure (such as shortness of breath, fatigue, and exercise intolerance); 2) cardiac output >8 L/min or cardiac index >3.9 L/min/m2; and 3) ejection fraction (EF) >50% and venous oxygen saturation >75%.48 Due to abnormal vascular flow through AVMs of the liver or lung, the vasculature may dilate because of increased high flow and/or decreased resistance. This causes the heart to compensate for the lower blood pressure with an increase in heart rate and output, leading to high-output failure. In these HHT patients, anemia may lead to an increased risk of heart failure due to the stress imposed from tachycardia and increased stroke volume.

**Epistaxis**

Epistaxis will manifest in approximately 50% of patients by the age of ten years. This increases with age such that 95% of all HHT patients eventually develop recurrent epistaxis.49 This will become evident in adulthood with consequent iron deficiency anemia.

**Gastrointestinal bleeding**

When significant, gastrointestinal bleeding affects approximately 20% of patients. GI telangiectasias and
AVMs can involve the large and small intestines as well as the stomach.

Central nervous system manifestations
Central nervous system manifestations may affect up to 10% of patients with HHT. Cerebral AVMs can be symptomatic and multiple in number, and are often present at birth. Neurological involvement may result in epilepsy, transient ischemic attack, stroke, or spinal hemorrhage. In addition to embolic strokes and hemorrhage, CNS infections such as brain abscesses may occur in 1% or more of patients, ranging in severity from mild to life-threatening. They are likely a result of bacterial seeding or septic emboli from ischemic brain matter or pulmonary AVMs.

Skin telangiectasias
Skin telangiectasias can be seen on the fingertips, tongue, face, lip, mucosa, and arms in up to 90% of patients (Figure 2). These sites can bleed and can be treated with laser ablation.

Iron deficiency/iron deficiency anemia
Iron deficiency/iron deficiency anemia is common in HHT. The underlying cause of iron deficiency in this patient population is the chronic blood loss from telangiectasias (e.g. nasal mucosa or intestinal tract) leading to iron store depletion. Approximately 5% of patients with HHT may have severe hemorrhages from epistaxis and/or intestinal AVMs. This consequently leads to a microcytic or normocytic anemia and symptoms of fatigue. Cardiopulmonary complications as described above can develop.

Other events
Though other events are not frequently reported, they include thromboembolic disease, pulmonary hypertension, liver disease, high-risk pregnancies, and spinal events. There is a 1% risk of mortality during pregnancy due to hemorrhage from cerebral or pulmonary AVMs. Patients are also affected socially and psychologically due to uncontrolled bleeding episodes. They commonly face difficulties with work, travel, social phobias, isolation, anxiety, and depressive disorders.

Juvenile polyposis
Juvenile polyposis is a rare association with HHT and results from a germline mutation in MADH4. This condition is also an autosomal dominant disorder. Mutations in MADH4 may manifest phenotypically as juvenile polyposis alone, HHT alone, or the combined syndrome of JP-HHT. The polyposis is best characterized by numerous hamartomatous polyps (i.e. 5-100) that are typically benign, but some patients may develop gastric or colorectal cancer, and so screening is encouraged. Patients with JP-HHT associated with MADH4 mutations are at an increased risk for early colorectal cancer. These patients may also have thoracic aorta dilation.

Diagnosis
Hereditary hemorrhagic telangiectasia is primarily a clinical diagnosis based on the following Curaçao criteria:
- spontaneous and recurrent epistaxis

| Table 2. Screening and management of hereditary human telangiectasia patients. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Anemia           | Epistaxis       | Gastrointestinal bleeding | CNS AVM |
| Evaluate for blood transfusion and iron requirements | Otolaryngology evaluation | Evaluation for telangiectasias and AVMs with upper endoscopy, colonoscopy, capsule endoscopy | MRI/MRA brain |
| Monitor ferritin, reticulocytes, hemoglobin | Humidification | Antifibrinolytics, estrogen or progesterone therapy, surgery, and embolization | >1 cm in diameter: neurosurgical evaluation, embolotherapy, +/- stereotactic radiosurgery |
| Start oral iron to maintain transferrin saturation >20% and ferritin >50 ng/mL | Nasal moisture with spray/ointment | Antifibrinolytics, estrogen or progesterone therapy, laser therapy, surgery, and embolization | Pulmonary AVM |
| IV iron: 1 g over multiple infusions | Electrocautery or laser therapy | CNS AVM |
| | Antifibrinolytics, estrogen or progesterone therapy, surgery, and embolization | Pulmonary evaluation |
| | | Transthoracic echocardiogram with bubble study for screening |
| | | +/- CT/CTA |
| | | If I+ bubbles on echocardiogram: avoid scuba diving, use IV with filters, antibiotic prophylaxis for procedures (amoxicillin or clindamycin if PCN allergic) |
| | | Consider embolization |
| | | Hepatic AVM |
| | | Abdominal ultrasound screening +/- CT/MRI |
| | | Consider embolization/ligation, liver transplantation |
| | | Other |
| | | Genetic consultation |
| | | Evaluation for other bleeding disorders |
| | | Discussion regarding anticoagulation, antiplatelet agents |
| | | Pregnancy is considered high risk |
| | | Consider assessment for hypercoagulability |

Figure 2. Clinical manifestations of telangiectasias. (A) Small red telangiectasias are often seen on the skin of hereditary hemorrhagic telangiectasia patients. (B) Similar lesions may be present on the tongue, lips, or palate.
• telangiectasias at characteristic sites
• visceral arteriovenous malformations or telangiectasias
• a first degree relative with HHT (inheritance is usually autosomal dominant).

Patients are classified as follows:
  3-4 criteria: definite HHT
  2 criteria: probable HHT
  0-1 criteria: HHT unlikely.

Genetic testing can be performed to inform family members, to increase patient awareness, and can guide more focused preventative screening and in cases of uncertainty. For patients with all 4 features present, the clinical sensitivity of the 5 gene HHT panel (assessing for pathogenic mutations in ENG, ACVRL1, MADH4, RASA1, and BMP9) is approximately 87% or higher. Although there has recently been an increase in awareness of HHT, it has been estimated that only 10% of all HHT patients are formally diagnosed; this is because of minimal symptoms or the fact that caregivers are not familiar with the disease and its diagnostic criteria.

Assessment and management

The prevention of future HHT complications is as important as treating the immediate active issues (e.g. bleeding) in caring for patients with HHT. Patients are often asymptomatic from undiagnosed AVMs that can lead to significant morbidity and mortality. Knowledge of a patient’s genetic mutation or family history may help confirm the urgency of certain screening tests over others. As outlined in Table 2, the following are relevant measures for identifying potentially significant AVMs: 1) brain magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA), 2) transthoracic echocardiogram with bubble study, followed by computed tomography (CT) scan as appropriate; 3) colonoscopy/endoscopy/video capsule endoscopy; 4) abdominal doppler ultrasound of the liver, followed by CT scan or MRI as indicated; 5) full ENT evaluation (especially if the patient has epistaxis); and 6) skin evaluation. Hematologic evaluation must also include complete blood count, reticulocyte count, erythrocyte sedimentation rate, iron, total iron binding capacity and ferritin. Ferritin levels alone may not accurately reflect iron stores due to the increased inflammation seen in many HHT patients. Consideration should be given to assessment for inherited thrombophilias prior to using antifibrinolytics for treatment of bleeding associated with HHT.

Treatment options are patient-specific and are best grouped by local versus systemic measures in a stepwise approach. There are no standard medical therapies for HHT given the few randomized trials in this field. Management can include supportive care, lesion-specific therapy, and systemic treatment. Lesion-specific therapy may call for involvement from otolaryngology, interventional radiology and neurosurgery.

Management of epistaxis

The first step in epistaxis management should always be appropriate patient counseling and use of preventive measures within the home to prevent the nasal mucosa from becoming dry. These may include nasal humidification, use of over-the-counter saline sprays or ointments to keep the nasal mucosa moist, and avoidance of nasal trauma (i.e. from nose blowing and/or nose picking).

When epistaxis occurs that does not cease within a short period of time at home, nasal packing and direct use of topical agents such as tranexamic acid-soaked gauze in an outpatient clinic or emergency room setting may help curtail bleeding but may also increase trauma to the nasal mucosa. Additional local measures that are commonly employed to control bleeding include laser treatments to the nasal mucosa and septodermoplasty. Historically, laser photoagulation and other interventional procedures have been the cornerstone of therapy, although this may begin to shift with effective disease-modifying systemic therapeutics on the horizon, detailed later in this review. Nasal closure is an effective but extreme form of therapy that is rarely used.

Management of epistaxis with antifibrinolytic agents is another consideration when preventive measures and local or topical treatments fail. Hyperfibrinolysis contributes to the bleeding phenotype in HHT and antifibrinolitics may work to inhibit fibrinolysis on the telangiectatic wall. By preventing fibrin degradation from plasmin, these agents may act to slow bleeding. Epsilon-aminocaproic acid and tranexamic acid can be considered in the care of patients with moderate or severe epistaxis.

In a randomized, double-blind, placebo-controlled, crossover study of 22 patients, tranexamic acid 1 g 3 times daily resulted in a 54% reduction in nosebleeds while on tranexamic acid as compared with the placebo treatment period, although there was no statistically significant improvement in hemoglobin concentration.

Apart from its inhibition of plasmin, tranexamic acid may have some effect on the underlying disease process; it appears to increase endoglin and ALK1 levels on the endothelium, selectively stimulating the TGF-β pathway.

In a randomized, double-blind, placebo-controlled, crossover study of 22 patients, tranexamic acid 1 g 3 times daily resulted in a 54% reduction in nosebleeds while on tranexamic acid as compared with the placebo treatment period, although there was no statistically significant improvement in hemoglobin concentration.

Dosing can be titrated upward if tolerable to tranexamic acid 650-1300 mg orally 3 times daily or aminocaproic acid 500-2000 mg orally every 4-8 hours. Other non-specific hemostatic agents, such as desmopressin or factor replacement products, are not optimal management as HHT is not a disease of coagulation factor deficiency. Antifibrinolitics should be avoided in patients with hypercoagulable conditions and/or prior thrombotic events.

While the evidence for its use is limited, N-acetylcycteine dosed 600 mg 3 times daily was modestly effective in reducing epistaxis in HHT patients in a pilot study, with the only statistically significant benefit seen in male patients and those with ENG mutations (HHT1).

Management of GI bleeding

Evidence of GI bleeding or a sharp decline in hematocrit without epistaxis should involve a prompt GI evaluation and an upper and lower endoscopy and, if these do not provide clear results, consideration of video capsule endoscopy. Telangiectasias and AVMs may be visualized in the esophagus, stomach, small intestine and/or colon. If accessible, local endoscopic treatment should be attempted. Patients with recurrent bleeding, multiple AVMs, and small bowel AVMs may require additional pharmacological measures. As in the management of epistaxis, antiangiogenic, antifibrinolytic agents and/or other hormonal agents may be considered. Octreotide therapy has also been proposed in reducing transfusion needs but is without much supporting data. Management of the ane-
mania and iron deficiency that result from this blood loss is addressed below.

**Management of pulmonary, hepatic, and CNS AVMs**

Collaboration with a pulmonologist, hepatologist, gastroenterologist, neurologist, neurosurgeon, and interventional radiologist with experience in treating HHT patients is crucial to the management of AVMs found in the lungs, liver, or brain. Screening is, therefore, important early in the diagnosis of these patients. Management will depend on the size of the AVMs, symptoms and location, and may include embolization of a pulmonary AVMs, surgical intervention for a CNS AVM and/or continued surveillance. Angiographic treatment of hepatic AVMs may be helpful in some patients but is often considered a higher risk by interventional radiologists.

**Management of iron deficiency anemia**

The development of anemia can have significant consequences for the patient with HHT. Although oral iron (e.g., ferrous sulfate 325 mg 3 times daily, ferrous asparto glycinate-polysaccharide iron complex 150 mg capsules 1-3 times daily) may be adequate for mildly affected HHT patients, many require intravenous iron such as ferumoxytol, iron sucrose or ferric carboxymaltose. Some patients may require 500-1000 mg of iron a month. Sometimes red blood cell (RBC) transfusion support is needed, but chronic RBC transfusion carries risk of infections and can lead to transfusion reactions and alloimmunization. In some patients, supplementation with erythroid stimulating agents (e.g. epoetin alfa, darbepoetin alfa) may be helpful. A suggested approach to the anemic HHT patient is presented in Figure 3.

**Use of hormonal agents**

Estrogen and progestins (e.g. ethinyl estradiol, norethindrone or mestranol) have been used in HHT patients to reduce bleeding complications. Mestranol or norethindrone may help increase nasal squamous epithelium and protect nasal lesions from injury. This hormonal therapy, however, can result in gynecomastia and/or loss of libido in men, weight gain, coronary events, and venous thromboembolism (VTE). Given the age of some patients and the potential side effects of this treatment, it has not been widely used. The overall improvement in hematologic parameters is also questionable.

Other hormonal treatment options include danazol 200 mg 3-4 times oral daily, tamoxifen 20 mg oral daily or raloxifene 60 mg oral daily. But these are not widely used.

**Use of novel systemic anti-angiogenic therapies**

Anti-VEGF therapies are relatively new for patients with HHT, and their use has been increasing. Thalidomide, used commonly in the management of multiple myeloma, is thought to have both vascular and immunomodulatory effects. Its antiangiogenic activity may be due to the suppression of production of VEGF and basic fibroblast growth factor (bFGF). Serum levels of VEGF were found to be decreased after thalidomide treatment in patients with GI bleeding. Nasal mucosal biopsies in HHT patients with epistaxis treated with thalidomide demonstrated vessel maturation and improved vessel wall defects.

Bevacizumab, an anti-VEGF antibody, is a rational therapeutic for HHT as it may reduce excessive angiogenesis (Figure 4). To date, all of the studies describing the use of systemic bevacizumab for the management of HHT have been retrospective cohorts, small case series, or single patient case reports (Table 3). A very recent retrospective study by Iyer et al. describes a large cohort of HHT patients receiving bevacizumab to treat GI bleeding and epistaxis. Thirty-four patients were given intravenous bevacizumab according to a standardized protocol, resulting in a statistically significant reduction in epistaxis sever-
ity scores and RBC transfusion requirements, although 4 patients developed new-onset or worsened hypertension. Most published studies have used bevacizumab at a dose of 5-10 mg/kg every 2-4 weeks for up to 6 cycles. A lower dose may be sufficient based on pharmacokinetic data showing VEGF suppression at 0.3 mg/kg. Adverse effects of bevacizumab may include hypertension, proteinuria, venous thromboembolism, intestinal perforation, and poor wound healing. Interestingly, epistaxis, which is often cited as a side effect in non-HHT patients, has not been a major complication in published studies or in our center’s extensive experience. Bevacizumab may have an impact on high output states in reducing cardiac output. In one study, 25 patients with severe hepatic vascular AVMs were treated with bevacizumab 5 mg/kg every 14 days for 6 cycles and showed an improvement in cardiac index at three months, reduced epistaxis, and improved quality of life. Bevacizumab nasal spray has been studied as a treatment for epistaxis. In a randomized phase I study (the ELLIPSE study), 40 patients received a single day treatment of 0.05-0.1 mL of (dose escalated) bevacizumab nasal spray into each nostril for a total dose of 12.5-100 mg. Initial results suggested that intranasal treatment was safe but not effective.

Use of anticoagulation in patients with thrombosis

Patients who develop thrombotic complications present a difficult therapeutic dilemma given the inherent bleeding of the disease. The low serum iron levels in HHT patients have been associated with elevated factor VIII levels, along with a 2.5-fold increased risk of VTE events. In those patients who develop a VTE, therapeutic anticoagulation can be administered. This should be managed with caution and the patient should be screened for pul-

Table 3. Published data using bevacizumab to treat chronic bleeding in hereditary human telangiectasia are patients.

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Patient number</th>
<th>Dosing</th>
<th>Duration of efficacy</th>
<th>Effect on epistaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bose 2009⁷</td>
<td>U.S.</td>
<td>1</td>
<td>10 mg/kg every 2 weeks x 2 cycles then 5 mg/kg every 2 weeks x 2 cycles</td>
<td>12 months</td>
<td>Immediate improvement</td>
</tr>
<tr>
<td>Oosting 2009⁸</td>
<td>the Netherlands</td>
<td>1</td>
<td>5 mg/kg every 2 weeks or 7.5 mg/kg every 2 weeks</td>
<td>12 months</td>
<td>Immediate improvement</td>
</tr>
<tr>
<td>Brinkerhoff 2011⁹</td>
<td>U.S.</td>
<td>1</td>
<td>5 mg/kg every 2 weeks x 4 cycles</td>
<td>12 months</td>
<td>Resolution after 4 cycles</td>
</tr>
<tr>
<td>Thompson 2014⁰</td>
<td>U.S.</td>
<td>9</td>
<td>0.125 mg/kg IV every 4 weeks x 8 cycles</td>
<td>6 months</td>
<td>Improvement in frequency and severity after 3 cycles on average</td>
</tr>
<tr>
<td>Epperla 2016¹</td>
<td>U.S.</td>
<td>5</td>
<td>5 mg/kg every 2 weeks x 6 cycles</td>
<td>12 months</td>
<td>Reduced need for nasal cautery procedures</td>
</tr>
<tr>
<td>Guilhem 2017⁴</td>
<td>France</td>
<td>36 treated for bleeding</td>
<td>5 mg/kg every 2 weeks x 6 cycles</td>
<td>6 months (median)</td>
<td>78% of patients had improved bleeding by physician assessment</td>
</tr>
<tr>
<td>Iyer 2018⁵</td>
<td>U.S.</td>
<td>34</td>
<td>5 mg/kg every 2 weeks x 4 cycles, with modification of dosing depending on response</td>
<td>6.4 months (median), intermittent treatment</td>
<td>Significant improvement in epistaxis severity scores</td>
</tr>
</tbody>
</table>

HHT: hereditary hemorrhagic telangiectasia; IV: intravenous.
monary and cerebral AVMs that may increase their bleeding risk.

**Clinical trials and future directions**

There are several ongoing clinical trials studying new therapies for HHT (Online Supplementary Table S1). HHT is relatively unique in the family of rare bleeding disorders in that several off-the-shelf therapeutics, such as bevacizumab, and the immunomodulatory agents (ImiDs) currently being used are rational targeted therapies that may be highly effective. The majority of studies are currently investigating the use of bevacizumab via different routes of administration (submucosal, topical or intravenous). In a murine model of HHT, four anti-angiogenic agents were studied for their impact on AVM formation. Sorafenib (a dual Raf kinase/VEGF receptor inhibitor with additional tyrosine kinase targets) and a pazopanib analog (pazopanib is a multi-target tyrosine kinase inhibitor with anti-VEGF receptor properties) were beneficial in improving anemia from bleeding from the GI tract more than from mucocutaneous lesions in the upper aerodigestive tract. A phase II study is being conducted to examine the efficacy of increasing doses of pazopanib, from 50 mg to 400 mg daily, in reducing epistaxis and improving anemia.

Tacrolimus, a calcineurin inhibitor used principally as an immunosuppressive therapy, may have a therapeutic role in HHT. Ruiz et al. identified tacrolimus as an activator of the ALK1-SMAD1/5/8 pathway, improving defects caused by ALK1 loss. Their data in human embryonic vascular endothelial cells demonstrated that tacrolimus activated ALK1 HHT mutants unresponsive to BMP9, and inhibited Akt and p38 stimulation by VEGF (normally a major driver of angiogenesis). In a mouse model of HHT, hypervascularization and AVMs were reduced in number by treatment with tacrolimus. Tacrolimus may, therefore, represent yet another off-the-shelf pharmacological option of potential therapeutic benefit in HHT patients.

Lastly, the aforementioned ImiDs are promising. In comparison with thalidomide and lenalidomide, pomalidomide may be a superior potential therapeutic option due to its efficacy and reduced toxicity (such as less peripheral neuropathy and cytopenias). Interim results from a phase I study of pomalidomide in HHT patients have been reported in which its use was associated with reduced bleeding outcomes in a small cohort of patients. Larger studies are needed to better evaluate the efficacy of this and other ImiDs in the management of bleeding in HHT.

Future directions in HHT may look to evaluate other antiangiogenic agents and other targets of the vascular endothelium. In patients with Heyde syndrome, acquired VWF deficiency in the plasma due to loss of large multimers of VWF from high shear stress may prove useful in the development of novel HHT therapies. In conclusion, HHT is a rare but poorly recognized genetic bleeding disorder that demands greater attention in order to develop targeted and rational management strategies that are both safe and cost-effective.

**References**

1442


